Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Standard Culture Versus Advanced Guidance UTI® Testing in Older Adults (SAGE UTI)

10 november 2026 bijgewerkt door: Pathnostics

SAGE-UTI: Standard Culture Versus Advanced Guidance UTI® Testing in Older Adults: a Single-blind Randomized Controlled Trial Evaluating Outcomes in UTI

The goal of this clinical trial is to compare two urine testing methods used to diagnose urinary tract infections (UTIs) in adults aged 60 years and older.

The main question this trial aims to answer is:

Does Guidance® UTI testing, compared with standard urine culture, improve patient outcomes and help healthcare providers make more appropriate antibiotic treatment decisions?

Participants will:

  • Be randomly assigned to either Guidance UTI testing or standard urine culture testing.
  • Provide a urine sample during their initial clinic visit.
  • Complete questionnaires at the initial visit and approximately 14 and 28 days later.

Researchers will compare UTI-related repeat medical visits, emergency care, hospitalizations, new UTI diagnoses, and antibiotic treatment decisions between the two groups.

Studie Overzicht

Gedetailleerde beschrijving

**Background and Rationale**

Urinary tract infections (UTIs) are common among older adults, particularly those with recurrent infections or underlying urinary tract conditions. Standard urine culture has limitations, including delayed results, incomplete detection of certain pathogens, and challenges identifying infections involving multiple organisms. These limitations may contribute to empiric antibiotic prescribing, inappropriate treatment, and adverse clinical outcomes.

Guidance® UTI combines multiplex polymerase chain reaction (M-PCR) for microbial identification and resistance gene detection with pooled antibiotic susceptibility testing (P-AST). This approach provides microbial identification and antibiotic susceptibility results within approximately 48 hours of laboratory receipt.

**Trial Design**

SAGE-UTI is a prospective, multicenter, single-blind, randomized controlled trial comparing Guidance UTI testing with standard urine culture in adults aged 60 years and older presenting with suspected UTIs.

Following informed consent and confirmation of eligibility, participants will be randomized in a 1:1 ratio to one of two diagnostic testing pathways:

  • **Arm A - Guidance UTI:** Urine specimens will undergo molecular microbial identification and pooled antibiotic susceptibility testing.
  • **Arm B - Standard Urine Culture:** Urine specimens will undergo standard urine culture and antibiotic susceptibility testing, as available, according to routine clinical practice.

All urine specimens will be processed at the Pathnostics central laboratory. Treating clinicians will receive results corresponding to the assigned diagnostic pathway and will make antibiotic treatment decisions based on clinical judgment and routine practice. Results from the alternative testing pathway will remain blinded unless disclosure is medically necessary for participant safety or appropriate clinical management.

**Trial Procedures**

Participants will undergo a baseline clinical assessment, urine specimen collection, and documentation of relevant medical history, symptoms, and antibiotic treatment.

Treating clinicians will complete a treatment decision survey following review of the assigned diagnostic results. Participants will complete follow-up assessments at approximately Days 14 and 28 to document clinical outcomes and UTI-related healthcare utilization.

Residual urine specimens will also be evaluated for exploratory urinary biomarkers, including interleukin-1 beta (IL-1β), interleukin-8 (IL-8), and neutrophil gelatinase-associated lipocalin (NGAL), to explore their relationship with diagnostic findings and clinical outcomes. These exploratory results will not be reported to treating clinicians.

**Clinical Significance**

The trial will evaluate whether Guidance UTI testing, compared with standard urine culture, improves clinical outcomes and supports more appropriate antibiotic prescribing in older adults with suspected UTIs. The findings may help inform diagnostic testing strategies, improve UTI management, and support antimicrobial stewardship.

Studietype

Observationeel

Inschrijving (Geschat)

2000

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

60 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Individuals ≥ 60 years old requiring evaluation for suspected urinary tract infection, whose clinical management will be impacted by the provided results, seen in outpatient urology or urogynecology specialty practice

Beschrijving

nclusion Criteria:

  • Able to provide written informed consent
  • Male and female subjects ≥ 60 may participate with no predetermined quotas or ratios for gender participation.
  • A history of (at least one): a) recurrent UTIs (defined as ≥ 2 UTIs within a 6 month period in the last 12 months) b) urinary tract obstruction (including urinary retention or hydronephrosis) and/or urinary tract injury (i.e. nephrolithiasis, ureteral or urinary stent placement, or any urologic surgery or instrumented procedure) within the last 24 months
  • Must present at the time of enrollment with clinically suspected active UTI (any lower urinary tract symptoms)
  • Must have positive chemical (dipstick) urinalysis (defined as nitrite "positive" and/or leukocyte esterase > "trace" by chemical urinalysis) performed at the baseline (Day 1) visit.
  • Management requires microbial identification and antibiotic sensitivities from urine
  • Able to provide a urine specimen (midstream voided or catheter collected)

Exclusion Criteria:

  • Subjects with indwelling catheter (suprapubic or foley) or are chronically reliant on intermittent self-catheterization
  • Subjects with suspected pyelonephritis, febrile UTI, or bacteremic UTI (as indicated by one or more of the following symptoms: fever, chills, rigors, hemodynamic instability, flank pain, costovertebral angle tenderness)
  • Subjects with suspected prostatitis (presence of tender, enlarged, or boggy prostate on digital rectal examination; history of prostate biopsy or surgery in previous 30 days)
  • Currently receiving radiation therapy in the pelvic region
  • Subjects with history of unstable, untreated, or are failing treatment for overactive bladder (either neurogenic or non-neurogenic)
  • Subjects with history of bladder malignancy in the past 3 years
  • Subjects that have been treated with chemotherapy in the past 3 years
  • Inability to independently complete subject surveys (i.e. unable to read or hear survey questions and respond appropriately)
  • Incarceration
  • Pregnancy

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: OTHER
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Arm A - Guidance UTI

Urine specimens will undergo molecular microbial identification and pooled antibiotic susceptibility testing.

Arm B - Standard Urine Culture:

Urine specimens will undergo standard urine culture and antibiotic susceptibility testing, as available, according to routine clinical practice.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percent difference between diagnostic test arm in the number of composite negative outcomes
Tijdsspanne: 28 days

Percent difference between diagnostic test arm in the number of composite negative outcomes (e.g., return visit to provider for UTI, ER visit for UTI, urgent care visit for UTI, hospitalization for UTI, new UTI diagnosis)

28 days

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percent difference between diagnostic test arm in: • The number of adverse events • The number of subjects empirically treated • The number of changes to antibiotic(s) prescribed
Tijdsspanne: 28 days

Percent difference between diagnostic test arm in:

  • The number of adverse events
  • The number of subjects empirically treated
  • The number of changes to antibiotic(s) prescribed
28 days
Differences in microbial identification, quantitation, and antibiotic susceptibility results between the two test results for the same subject
Tijdsspanne: 28 days

Differences in microbial identification, quantitation, and antibiotic susceptibility results between the two test results for the same subject

28 days
Percentage of directed antibiotic prescriptions that are concordant with susceptibility testing result(s)
Tijdsspanne: 28 days

Percentage of directed antibiotic prescriptions that are concordant with susceptibility testing result(s)

28 days
Relative frequency with which result components and other factors are reported to influence antibiotic prescribing decisions
Tijdsspanne: 28 days

Relative frequency with which result components and other factors are reported to influence antibiotic prescribing decisions

28 days

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

14 december 2026

Primaire voltooiing (Geschat)

14 december 2027

Studie voltooiing (Geschat)

14 december 2027

Studieregistratiedata

Eerst ingediend

23 oktober 2026

Eerst ingediend dat voldeed aan de QC-criteria

10 november 2026

Eerst geplaatst (Werkelijk)

17 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren